A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants

NCT07722299 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

DRUG: SAL0167 group
DRUG: SAL0167 placebo group

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.